Skip to main content

High Grade Cervical Intraepithelial Neoplasia

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nykode Therapeutics
Nykode TherapeuticsNorway - Oslo
1 program
1
VB10.16 ImmunotherapyPhase 1/21 trial
Active Trials
NCT02529930Completed34Est. Jan 2019
DYSIS Medical
DYSIS MedicalMA - Natick
1 program
DySISN/A1 trial
Active Trials
NCT02185599Completed7,555Est. Oct 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nykode TherapeuticsVB10.16 Immunotherapy
DYSIS MedicalDySIS

Clinical Trials (2)

Total enrollment: 7,589 patients across 2 trials

NCT02529930Nykode TherapeuticsVB10.16 Immunotherapy

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Start: Aug 2015Est. completion: Jan 201934 patients
Phase 1/2Completed

IMproved PRactice Outcomes and Value Excellence in Colposcopy

Start: Sep 2014Est. completion: Oct 20177,555 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.